Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Electronic cigarettes pose particular risks to the developing brains, organs of young people

Electronic cigarettes pose particular risks to the developing brains, organs of young people

Although heavily promoted as a safer cigarette and an aid to quit smoking, electronic cigarettes and the nicotine they deliver pose particular risks to the developing brains and organs of children. Use of electronic cigarettes by school-age children has surpassed traditional cigarette smoking, and it is critical to recognize and understand the risks related to nicotine exposure, addiction, and the poor regulation of these products, as described in the comprehensive Review article "Electronic Cigarettes: Vulnerability of Youth," published in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Novel treatment strategy targets treatment-resistant CML

Novel treatment strategy targets treatment-resistant CML

Researchers have shown that the coiled-coil mimetic CCmut3 can inhibit cell growth and promote apoptosis in cell lines expressing BCR–ABL1, including those resistant to tyrosine kinase inhibitors. [More]
Intelligent Hospital Association recognizes Ochsner with Best Comprehensive Integration award

Intelligent Hospital Association recognizes Ochsner with Best Comprehensive Integration award

The Intelligent Hospital Association today announced that Ochsner Health System was awarded the Best Comprehensive Integration for 2014. The award is given to a hospital or health system that effectively and seamlessly integrates technologies to provide a comprehensive solution in a health care facility. [More]
CareFusion showcases new medication management technologies at HIMSS annual conference

CareFusion showcases new medication management technologies at HIMSS annual conference

CareFusion, a BD company, today announced it is demonstrating several new medication management technologies at the Healthcare Information Management and Systems Society annual conference in the Intelligent Health Pavilion and Interoperability Showcase. [More]

Particle Sciences receives patent for its surface arrayed therapeutics drug delivery platform

Particle Sciences, a leading drug delivery CDMO, has received a Notice of Allowance for composition and use of the technology incorporated into its SATx™ platform... [More]
Prolong Pharmaceuticals' SANGUINATE granted FDA Orphan Drug Designation for SCD treatment

Prolong Pharmaceuticals' SANGUINATE granted FDA Orphan Drug Designation for SCD treatment

Prolong Pharmaceuticals, LLC, a biopharmaceutical company dedicated to developing products for the treatment of anemias, cancers and their debilitating comorbidities, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its flagship product SANGUINATE for the treatment of Sickle Cell Disease (SCD). [More]

Watching the blood flow

Optical microangiography (OMAG), a technique based on optical coherence tomography, can be used to visualize the microvasculature network under inflamed skin condition. It opens up new vistas for clinical trials of treatment and diagnosis of inflammatory skin disorders. [More]
Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. [More]
Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Columbia Laboratories, Inc., today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol — "JNP" — on Monday, April 13, 2015. [More]
BioLight forms strategic partnership with Rock-One to expand its presence within China

BioLight forms strategic partnership with Rock-One to expand its presence within China

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today an agreement to enter into a strategic partnership with Rock-One International Holdings Ltd., a holding company specializing in investment activities, including in the high tech and biomedical industries. [More]

University of York student helps develop new drug release gel

A Chemistry undergraduate at the University of York has helped to develop a new drug release gel, which may help avoid some of the side effects of painkillers such as ibuprofen and naproxen. [More]
Biomedical researchers successfully convert microbubble technology into nanoparticles

Biomedical researchers successfully convert microbubble technology into nanoparticles

Biomedical researchers led by Dr. Gang Zheng at Princess Margaret Cancer Centre have successfully converted microbubble technology already used in diagnostic imaging into nanoparticles that stay trapped in tumours to potentially deliver targeted, therapeutic payloads. [More]
Columbia licenses exclusive worldwide rights to novel intra-vaginal ring technology

Columbia licenses exclusive worldwide rights to novel intra-vaginal ring technology

Columbia Laboratories, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, has licensed exclusive worldwide rights to a novel intra-vaginal ring technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring. [More]

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

DURECT Corporation today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. [More]
Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed. [More]
MTI Expo 2015 to focus on engineering requirements in the medical technology sector

MTI Expo 2015 to focus on engineering requirements in the medical technology sector

April 29-30, Ricoh Stadium, Coventry sees the next edition of the Med-Tech Innovation exhibition take place – engineering is the thread that runs through the whole show. [More]
New targeted therapy promises to reduce frequency and intensity of breakouts

New targeted therapy promises to reduce frequency and intensity of breakouts

Acne, a scourge of adolescence, may be about to meet its ultra high-tech match. By using a combination of ultrasound, gold-covered particles and lasers, researchers from UC Santa Barbara and the private medical device company Sebacia have developed a targeted therapy that could potentially lessen the frequency and intensity of breakouts, relieving acne sufferers the discomfort and stress of dealing with severe and recurring pimples. [More]
Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

Late stage pancreatic cancer benefits from photodynamic therapy (PDT) but the resources needed for the usual accompanying dosimetry present barriers, Dartmouth researchers Jonathan T. Elliott, PhD and Brian C. Pogue, PhD have mitigated by using common clinical technologies. [More]
Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO). [More]
Sandia biosciences technologies could soon find their way into doctors' offices

Sandia biosciences technologies could soon find their way into doctors' offices

Technologies developed in Sandia National Laboratories' biosciences program could soon find their way into doctors' offices -- devices like wearable microneedles that continuously analyze electrolyte levels and a lab-on-a-disk that can test a drop of blood for 64 different diseases in minutes. [More]
Advertisement
Advertisement